TB-500 and thymosin beta-4
Thymosin beta-4 is a naturally occurring peptide involved in cell migration and wound repair, studied in wound healing and cardiac repair research. TB-500 is a related fragment sold online as a research chemical. Neither is approved for human use, and evidence for the marketed recovery claims is early.
What research shows about thymosin beta-4 and the TB-500 fragment sold online: animal and early clinical work, regulatory status, risks and unknowns.
A real research molecule, and a differently named product sold online.
Key takeaways
- Thymosin beta-4 is a genuine subject of tissue repair research.
- TB-500 as sold online is not identical to the full molecule studied in trials.
- No approval for human use; prohibited in sport.
- Human efficacy for injury recovery is not established.
The molecule versus the product
Most published research concerns thymosin beta-4 itself. TB-500 is a shorter fragment marketed on the strength of that research. Whether the fragment behaves like the parent molecule in people is an assumption, not a finding.
What the research supports
Preclinical evidence for roles in cell migration, angiogenesis and wound repair is reasonable, and some early clinical work exists in narrow settings. That is a long way from evidence for accelerating a torn tendon's recovery in an otherwise healthy adult.
Practical position
No approval, no adequate human efficacy data for the marketed use, unregulated supply, and a mechanism that raises open questions about tumour growth.
Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
Not exactly. TB-500 is a related fragment; most of the published research concerns the full peptide.
Is it allowed in sport?
No. It is prohibited under anti-doping rules.
Has it been proven to heal injuries in people?
No. There is no adequate randomised trial evidence for musculoskeletal recovery in humans.
Related on Beiing
- BPC-157 - The other widely marketed repair peptide.
- Peptides, recovery and tissue repair - The evidence landscape.
- How Beiing rates peptide evidence - The five evidence levels used in this section.
- Peptides & Human Biology - The hub for every page in this section.
Sources
- PubMed - National Library of Medicine - NIH
- ClinicalTrials.gov - U.S. National Library of Medicine
- FDA - Bulk Drug Substances Used in Compounding Under Section 503A - U.S. Food and Drug Administration
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.